A peer-reviewed study in Gut Microbes reports that Ewingella americana, a bacterium isolated from amphibian and reptile gut microbiomes, achieved complete tumor elimination in 100% of treated mice with colorectal cancer. Researchers administered a single intravenous dose to immunocompetent mouse models, observing no tumor recurrence even after re-exposure to cancer cells.

The bacterium operates through a dual mechanism: as a facultative anaerobe, it selectively accumulates in the hypoxic tumor microenvironment where it proliferates and directly kills cancer cells. Simultaneously, it triggers rapid immune infiltration with T cells, B cells, and neutrophils, alongside cytokine surges including TNF-α and IFN-γ. Within 24 hours, bacterial load increased approximately 3,000-fold within tumors, demonstrating efficient tumor homing.

In safety testing, treated animals showed no significant weight loss, organ toxicity, or hematologic abnormalities. The bacterium cleared from circulation within 24 hours while remaining localized in tumor tissue—a favorable pharmacokinetic profile. Notably, this therapeutic agent is naturally occurring, not genetically engineered, suggesting non-human microbiomes may contain untapped cancer treatments.

While these results require human validation, the preclinical outcomes represent a significant departure from conventional single-mechanism therapies. A single-dose intervention achieving complete eradication while outperforming both doxorubicin chemotherapy and anti-PD-L1 immunotherapy demands serious scientific attention.